Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Humanized hemato-lymphoid system mice. Haematologica (2016) 0.98

Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia. Stem Cells Int (2015) 0.82

Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells. J Hematol Oncol (2016) 0.78

Cancer stem cells in haematological malignancies. Contemp Oncol (Pozn) (2015) 0.77

Hypoxia and Hypoxia-Inducible Factors in Leukemias. Front Oncol (2016) 0.76

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World J Stem Cells (2016) 0.76

Parthenolide Induces Apoptosis in Committed Progenitor AML Cell line U937 via Reduction in Osteopontin. Rep Biochem Mol Biol (2016) 0.75

Targeting acute myeloid leukemia stem cell signaling by natural products. Mol Cancer (2017) 0.75

The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig (2017) 0.75

Shedding light on the DARC knight as a guardian of hematopoietic stem cell quiescence. Stem Cell Investig (2017) 0.75

Yi-qi-yang-yin-tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR. Oncol Lett (2017) 0.75

Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33

Primary bioassay of human tumor stem cells. Science (1977) 9.69

Cancer stem cells. N Engl J Med (2006) 9.63

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol (2010) 8.80

Stem cell concepts renew cancer research. Blood (2008) 6.74

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood (2002) 6.64

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell (2006) 6.34

Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 5.92

Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med (1978) 5.78

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 5.52

Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30

Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol (2007) 5.21

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol (2004) 5.10

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12

Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A (2003) 4.09

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 3.91

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood (2001) 3.90

Cancer stem cells: lessons from leukemia. Trends Cell Biol (2005) 3.90

Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A (1997) 3.84

Drug therapy for acute myeloid leukemia. Blood (2005) 3.74

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32

Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 3.22

Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A (2002) 3.12

Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96

BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell (2013) 2.92

ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells (2002) 2.90

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71

Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol (2001) 2.63

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood (2003) 2.60

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell (2009) 2.60

Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood (2012) 2.45

Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood (2002) 2.44

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res (2001) 2.35

Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood (1997) 2.33

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood (2013) 2.28

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood (2013) 2.26

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood (2004) 2.08

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03

CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 1.99

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood (2009) 1.98

Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res (2000) 1.94

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res (2005) 1.94

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood (2005) 1.93

The cancer stem cell hypothesis: a work in progress. Lab Invest (2006) 1.87

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood (2007) 1.81

Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med (2010) 1.78

Cancer stem cells: are we missing the target? J Natl Cancer Inst (2004) 1.72

Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood (2003) 1.60

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood (2013) 1.59

Concepts of human leukemic development. Oncogene (2004) 1.56

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood (2004) 1.49

Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood (1998) 1.44

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood (2001) 1.42

Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol (2005) 1.41

Current treatment of acute myeloid leukemia. Curr Opin Oncol (2012) 1.38

Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia (2007) 1.33

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol (2005) 1.33

Recent advances in acute myeloid leukemia stem cell biology. Haematologica (2012) 1.25

BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood (1993) 1.23

Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia (2002) 1.23

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia (2004) 1.23

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother (2002) 1.23

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood (2013) 1.21

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol (2003) 1.18

Stem cells: Self-renewal writ in blood. Nature (2003) 1.18

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia (2012) 1.18

Varying intensity of postremission therapy in acute myeloid leukemia. Blood (1992) 1.13

Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood (1997) 1.13

Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood (1996) 1.13

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood (2000) 1.11

A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res (2002) 1.09

Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol (2009) 1.08

Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell (2007) 1.07

Strategies to eliminate cancer stem cells: clinical implications. Eur J Cancer (2006) 1.02

A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med (2013) 1.01

Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma (2006) 0.97

Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia (2011) 0.95

Leukemia stem cells. Semin Cancer Biol (2009) 0.95

The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood (2013) 0.93

A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res (2006) 0.93

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia (2000) 0.91

Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction. Exp Hematol (2002) 0.88

Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities. Blood (2008) 0.87

Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia (2000) 0.86

The role of tumor stem-cells in regrowth of the tumor following drastic applications. Acta Unio Int Contra Cancrum (1959) 0.86

Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance. Exp Hematol (2011) 0.85

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. Leuk Res Treatment (2013) 0.84

A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): a Southwest Oncology Group study. Leukemia (1995) 0.84

Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia. Int J Lab Hematol (2012) 0.84

Remission induction in acute myeloid leukemia. Int J Hematol (2012) 0.83

Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. Blood (2017) 1.09

Therapeutic targeting of acute myeloid leukemia stem cells. Blood (2017) 0.75